Search clinical trials for: НМРЛ

Total 2138 results

Forward Pharmaceuticals Co., Ltd.
WuXi Clinical

Recruiting

A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer (FWD1509)

Carcinoma, Non-Small-Cell Lung

United States
Shanghai Henlius Biotech

Recruiting

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation

NSCLC

China
Genprex, Inc.

Recruiting

Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer (Acclaim-2)

Non Small Cell Lung Cancer

United States
Cancer Research UK
Hummingbird Bioscience

Recruiting

HMBD-001 in Advanced HER3 Positive Solid Tumours

Melanoma | Cervical Cancer | Gastric Cancer | Pancreatic Cancer | Ovarian Cancer | Hepatocellular Carcinoma (HCC) | Bladder Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Castration-resistant Prostate Cancer | Non-small Cell Lung Cancer (NSCLC) | Oesophageal Cancer | RAS Wild Type Colorectal Cancer | Squamous Cell Cancer of the Head and Neck

United Kingdom
Tang-Du Hospital

Recruiting

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

NSCLC Stage IV | Oligometastasis

China
AstraZeneca
Daiichi Sankyo

Recruiting

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China, Korea, Republic of, Germany, Italy, Poland, Belgium, Mexico, Turkey, Spain, France, United States, Canada, Taiwan, Brazil, Austria, Hong Kong, India, Japan, Netherlands, Denmark
Sichuan Cancer Hospital and Research Institute

Recruiting

Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.

Non-small Cell Lung Cancer | Esophageal Squamous Cell Carcinoma

China
National University Hospital, Singapore

Recruiting

Osimertinib for Advanced EGFR-positive NSCLC Patients

Non Small Cell Lung Cancer | EGFR Positive Non-small Cell Lung Cancer

Singapore
Hadassah Medical Organization

Recruiting

A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases

NSCLC | Non-small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | Brain Metastases | EGFR Gene Mutation

Israel
LMU Klinikum
Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich... and other collaborators

Recruiting

Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab (PRECISION)

Oncology | NSCLC, Stage III | Chemoradiotherapy | Biomarker | Durvalumab

Germany
Hubei Cancer Hospital

Recruiting

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

NSCLC

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

Non Small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer

China
Gruppo Oncologico Italiano di Ricerca Clinica

Recruiting

Alectinib in Neo-adjuvant Treatment of Stage III NSCLC (ALNEO)

Non Small Cell Lung Cancer

Italy
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

FIH Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation in China

NSCLC | Solid Tumor | CRC

China
Shanghai Chest Hospital

Not yet recruiting

A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. (CAMFA-L)

NSCLC

China
AbbVie

Recruiting

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab

Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

United States, Israel, Japan, Korea, Republic of
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

NSCLC | Advanced Solid Tumor | CRC

United States
Sheba Medical Center
Rambam Health Care Campus; AstraZeneca; Tel-Aviv Sourasky Medical Center

Recruiting

Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy (CORAL-Lung)

Metastatic or Locally Advanced NSCLC

Israel
Wuhan Union Hospital, China

Recruiting

18F-FDG PET/CT to Evaluate pD-1 Monoclonal Antibody With First-line Chemotherapy in Advanced NSCLC

NSCLC

China
Sophia Genetics SAS

Recruiting

Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer (DEEP-Lung-IV)

Non-small Cell Lung Cancer Metastatic

United States, Spain, France, Israel, Germany, Canada, Italy, Brazil
Sunshine Lake Pharma Co., Ltd.

Not yet recruiting

Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations

Advanced NSCLC
Dr Joanne CHIU

Recruiting

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

ALK Gene Rearrangement Positive | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Activating Mutation | Nsclc | ROS1 Gene Rearrangement | ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancer

Hong Kong
University Medical Center Groningen

Recruiting

CPAP or BiPAP for Motion Mitigation During Radiotherapy (SISTER)

Esophageal Cancer | NSCLC | Radiotherapy Side Effect | Malignant Lymphoma

Netherlands
Shandong Cancer Hospital and Institute

Recruiting

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Unresectable Stage III NSCLC

China
Regeneron Pharmaceuticals

Recruiting

Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

Advanced NSCLC

United States
A2 Biotherapeutics Inc.
Tempus AI

Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing (BASECAMP-1)

Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Neoplasms | Ovarian Cancer | NSCLC | Non Small Cell Lung Cancer | Mesothelioma | Mesothelioma, Malignant | Pancreas Cancer | Ovarian Carcinoma | Solid Tumor, Adult | CRC | Mesothelioma; Lung

United States
Li-kun Chen

Recruiting

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Brain Metastases

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Yuan Chen

Recruiting

Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

NSCLC, Stage III

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Non-small Cell Lung Cancer

China
Jianxing He

Not yet recruiting

Uniportal Tubeless VATS for the Evaluation of Biopsy for Second-generation Sequencing in Patients With Advanced NSCLC

NSCLC | VATS | Biopsy Technique | CT Guided Puncture Biopsy | NGS
Ruijin Hospital

Recruiting

Safety and Feasibility of Surgery After Conversion Therapy for Locally Advanced and Advanced NSCLC

Advanced Cancer | Locally Advanced Cancer | Pulmonary Neoplasm

China
Second Affiliated Hospital of Nanchang University
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis (ATTRACT)

NSCLC | EGFR Activating Mutation | Leptomeningeal Metastasis

China
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy

Advanced or Metastatic NSCLC

China
Gustave Roussy, Cancer Campus, Grand Paris
Daiichi Sankyo, Inc.

Recruiting

Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer (ICARUS-LUNG01)

Metastatic Lung Cancer

France
AstraZeneca

Recruiting

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

Carcinoma, Non-Small-Cell Lung | Gastric Cancer | Gastroesophageal Junction Cancer

United States, Canada, Spain, China, Japan, France, Turkey, Netherlands, Moldova, Republic of, Georgia
AbbVie

Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States, Argentina, Brazil, Bulgaria, Chile, Czechia, Greece, Italy, Japan, Korea, Republic of, Netherlands, Poland, Romania, Spain, Taiwan, Turkey, Australia, France, Sweden, Belgium, Denmark, China, Austria, United Kingdom, Germany and more
University Hospital Heidelberg

Recruiting

Magnetic Resonance Guided Adaptive Stereotactic Body Radiotherapy for Lung Tumors in Ultracentral Location (MAGELLAN)

Lung Cancer

Germany
Shanghai OriginCell Therapeutics Co., Ltd.

Not yet recruiting

An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung
Kinnate Biopharma

Recruiting

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Melanoma | Non-small Cell Lung Cancer | Solid Tumor, Adult

United States, Australia, France, Spain, Taiwan, Korea, Republic of, China, Netherlands
Radboud University Medical Center
Dutch Society of Physicians for Pulmonology and Tuberculosis

Recruiting

Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC (DEDICATION-1)

NSCLC

Netherlands
National University Hospital, Singapore
Boehringer Ingelheim

Recruiting

Observational Study of Afatinib 30 mg Daily

Non-Small Cell Lung Cancer | Epidermal Growth Factor Receptor Mutation

Singapore
Microbio Co Ltd

Recruiting

Safety and Potential Efficacy of MS-20 In Combination With Pembrolizumab for the Treatment of NSCLC

NSCLC Stage IV

Taiwan
Samsung Medical Center
National Evidence-Based Healthcare Collaborating Agency

Recruiting

The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients (OPTIMUS)

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of
Chongqing University Cancer Hospital

Recruiting

Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC

Non-Small Cell Lung Cancer (NSCLC)

China
Wuhan Union Hospital, China

Not yet recruiting

Monitoring the Efficacy of Duvalizumab Combined With Neoadjuvant Chemotherapy for Ib-IIIb NSCLC by Sequencing of Immune Receptor Repertoire: a Prospective, One Arm Clinical Study

Ib-IIIb NSCLC
Shanghai Chest Hospital
Allist Pharmaceuticals, Inc.

Recruiting

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (FOCUS-A)

Non-Small-Cell Lung Cancer

China
Bristol-Myers Squibb

Recruiting

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Melanoma | Carcinoma, Renal Cell | Cervical Cancer | Pancreatic Adenocarcinoma | Ovarian Neoplasms | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Urothelial Carcinoma | Microsatellite Stable Colorectal Cancer | Non-Small-Cell Lung Cancer | Gastric/Gastroesophageal Junction...

United States, Australia, Italy, Germany, Spain, Canada, Israel, Japan
University of Erlangen-Nürnberg Medical School

Recruiting

Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy (ST-ICI02)

Renal Cell Carcinoma | Esophageal Cancer | NSCLC | Urothelial Carcinoma | HNSCC | Squamous Cell Carcinoma of the Skin | Small Cell Bronchial Carcinomas

Germany

Search clinical trials for: НМРЛ

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations